[go: up one dir, main page]

MX2010008818A - Derivado de bicicloamina. - Google Patents

Derivado de bicicloamina.

Info

Publication number
MX2010008818A
MX2010008818A MX2010008818A MX2010008818A MX2010008818A MX 2010008818 A MX2010008818 A MX 2010008818A MX 2010008818 A MX2010008818 A MX 2010008818A MX 2010008818 A MX2010008818 A MX 2010008818A MX 2010008818 A MX2010008818 A MX 2010008818A
Authority
MX
Mexico
Prior art keywords
alkylene
represent
neuralgia
insomnia
epilepsy
Prior art date
Application number
MX2010008818A
Other languages
English (en)
Inventor
Fumihiro Ozaki
Toshihiko Kaneko
Noboru Yamamoto
Nobuyuki Kurusu
Kiyoaki Kobayashi
Yoshihiko Norimine
Motohiro Soejima
Tasuku Ishida
Eriko Doi
Daiju Hasegawa
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2010008818A publication Critical patent/MX2010008818A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Los compuestos representados por la fórmula (I) y las sales farmacéuticamente aceptables de los mismos tienen excelente acción inhibidora del canal de sodio y son útiles como agentes terapéuticos y analgésicos para varios tipos de neuralgia, neuropatía, epilepsia, insomnio, eyaculación precoz y lo similar. (Ver fórmula I) En donde Q representa etileno, etc., R1, R2 y R3 representan hidrógeno, etc., X1 representa alquileno C1-6, etc., X2 representa alquileno C1-4, etc., A1 representa un grupo heterocíclico de 5 a 6 miembros, etc., y A2 representa arilo C6-14, etc.
MX2010008818A 2008-02-13 2009-02-09 Derivado de bicicloamina. MX2010008818A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2837808P 2008-02-13 2008-02-13
JP2008031939 2008-02-13
PCT/JP2009/052164 WO2009101917A1 (ja) 2008-02-13 2009-02-09 ビシクロアミン誘導体

Publications (1)

Publication Number Publication Date
MX2010008818A true MX2010008818A (es) 2010-09-07

Family

ID=40956948

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010008818A MX2010008818A (es) 2008-02-13 2009-02-09 Derivado de bicicloamina.

Country Status (12)

Country Link
US (2) US8252810B2 (es)
EP (1) EP2241567A4 (es)
JP (1) JPWO2009101917A1 (es)
KR (1) KR20100124262A (es)
CN (1) CN101910169A (es)
AU (1) AU2009213488A1 (es)
CA (1) CA2714591A1 (es)
IL (1) IL206875A0 (es)
MX (1) MX2010008818A (es)
RU (1) RU2010137862A (es)
WO (1) WO2009101917A1 (es)
ZA (1) ZA201005769B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009216769A1 (en) * 2008-02-20 2009-08-27 Novartis Ag Heterocyclic inhibitors of stearoyl-CoA desaturase
EP2399910B1 (en) 2009-02-13 2014-04-02 Shionogi&Co., Ltd. Triazine derivatives as p2x3 and/or p2x2/3 receptor antagonists and pharmaceutical composition containing them
US8703759B2 (en) * 2010-07-02 2014-04-22 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
JP5594706B2 (ja) 2010-08-10 2014-09-24 塩野義製薬株式会社 トリアジン誘導体およびそれを含有する鎮痛作用を有する医薬組成物
EP2604260B1 (en) 2010-08-10 2017-05-10 Shionogi&Co., Ltd. Novel heterocyclic derivatives and pharmaceutical composition containing same
PL2707361T3 (pl) 2011-05-10 2018-01-31 Gilead Sciences Inc Skondensowane związki heterocykliczne stosowane jako modulatory kanału sodowego
NO3175985T3 (es) 2011-07-01 2018-04-28
TWI622583B (zh) 2011-07-01 2018-05-01 基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
US9328138B2 (en) 2011-11-15 2016-05-03 Msd Italia S.R.L. HCV NS3 protease inhibitors
JP6124351B2 (ja) 2012-02-09 2017-05-10 塩野義製薬株式会社 複素環および炭素環誘導体
TWI637949B (zh) 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
CN107349204A (zh) * 2017-07-11 2017-11-17 东新皓特（北京）生化科技有限公司 河豚毒素在制备治疗带状疱疹病症药物组合物中的应用、药物组合物及外用药
TW201945346A (zh) * 2018-04-10 2019-12-01 德商拜耳廠股份有限公司 2,4,5-三取代的1,2,4-三唑酮之製備方法
WO2021026375A1 (en) * 2019-08-07 2021-02-11 Alkermes, Inc. Fused bicyclic compounds for the treatment of pain
WO2021026378A1 (en) * 2019-08-07 2021-02-11 Alkermes, Inc. Indole compounds for the treatment of pain
WO2021026377A1 (en) * 2019-08-07 2021-02-11 Alkermes, Inc. Lactam-containing compounds for the treatment of pain

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3827264A1 (de) 1987-12-22 1989-07-13 Bayer Ag Verfahren zur herstellung von 4-amino-1,2,4-triazol-5-onen
US6248889B1 (en) 1998-11-20 2001-06-19 3M Innovative Properties Company Process for converting an alcohol to the corresponding fluoride
US6432976B1 (en) * 1999-10-29 2002-08-13 Merck & Co., Inc. 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists
WO2001053288A1 (en) 2000-01-20 2001-07-26 Eisai Co., Ltd. Novel piperidine compounds and drugs containing the same
US6833371B2 (en) 2001-11-01 2004-12-21 Icagen, Inc. Pyrazolopyrimidines
US7244744B2 (en) 2001-11-01 2007-07-17 Icagen, Inc. Piperidines
EP1451160B1 (en) 2001-11-01 2010-01-13 Icagen, Inc. Pyrazole-amides for use in the treatment of pain
EP1599472A1 (en) 2003-02-27 2005-11-30 F. Hoffmann-La Roche Ag Ccr-3 receptor antagonists
WO2004082621A2 (en) * 2003-03-15 2004-09-30 Bethesda Pharmaceuticals, Inc. Novel ppar agonists, pharmaceutical compositions and uses thereof
US20040220170A1 (en) 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
TW200533348A (en) * 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
MX2007007818A (es) * 2004-12-22 2007-09-11 Theravance Inc Compuestos de indazol-carboxamida.
GB0500300D0 (en) 2005-01-07 2005-02-16 Ionix Pharmaceuticals Ltd Chemical compositions
AR053713A1 (es) 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
US20090131412A1 (en) * 2005-06-07 2009-05-21 Dainippon Sumitomo Pharma Co., Ltd. Novel 2-quinolone derivative
WO2006133104A2 (en) * 2005-06-07 2006-12-14 Theravance, Inc. Benzoimidazolone-carboxamide compounds as 5-ht4 receptor agonists
GB0514018D0 (en) * 2005-07-07 2005-08-17 Ionix Pharmaceuticals Ltd Chemical compounds
NL2000284C2 (nl) 2005-11-04 2007-09-28 Pfizer Ltd Pyrazine-derivaten.
EP1984339A1 (en) 2006-01-23 2008-10-29 Pfizer Limited Pyridine derivatives as sodium channel modulators
WO2008016811A2 (en) * 2006-07-31 2008-02-07 Neurogen Corporation Aminopiperidines and realted compounds

Also Published As

Publication number Publication date
CN101910169A (zh) 2010-12-08
US20100331310A1 (en) 2010-12-30
RU2010137862A (ru) 2012-03-20
US8252810B2 (en) 2012-08-28
ZA201005769B (en) 2011-10-26
EP2241567A4 (en) 2011-11-09
EP2241567A1 (en) 2010-10-20
CA2714591A1 (en) 2009-08-20
IL206875A0 (en) 2010-12-30
AU2009213488A1 (en) 2009-08-20
WO2009101917A1 (ja) 2009-08-20
JPWO2009101917A1 (ja) 2011-06-09
US20090270369A1 (en) 2009-10-29
KR20100124262A (ko) 2010-11-26

Similar Documents

Publication Publication Date Title
MX2010008818A (es) Derivado de bicicloamina.
MY160424A (en) Substituted pyrrolidine-2-carboxyamides.
TN2009000199A1 (en) Heteromonocyclic compound and use thereof
TNSN08407A1 (en) Organic compounds
PH12016501822A1 (en) Cyclopropaneamine compound
CR20120053A (es) Compuestos y metodos inhibidores de jak de pirazolopirimidina
SG10201809895YA (en) Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
PH12012500903A1 (en) N1 - pyrazolospiroketone acetyl-coa carboxylase inhibitors
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
JO2967B1 (en) Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
TW200744586A (en) Therapeutic compounds
MY152972A (en) Azabicyclo compound and salt thereof
NO20091590L (no) Heterocykliske amidforbindelser anvendbare som kinaseinhibitorer
TW200612958A (en) Substituted imidazole derivatives
MX2009009238A (es) Nuevos inhibidores de fosfodiesterasa.
WO2012054721A8 (en) Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors
MX335989B (es) Compuesto adecuado para el tratamiento de sinucleopatias.
MX2012003982A (es) Pirrolidinas n-substituidas.
NZ592314A (en) Sulfoximine-substituted anilinopyrimidine derivatives as cdk inhibitors, the production thereof, and use as medicine
MX2009011749A (es) Compuestos triciclicos como inhibidores de metaloproteinasa matricial.
MX2010010502A (es) Inhibidores de desacetilasas b a base de hidroxamato.
MX2009012125A (es) Compuestos terapeuticos.
SI1753723T1 (sl) Substituirani kinolinski derivati kot mitotiäśni kinesinski inhibitorji
GEP20125389B (en) Substituted pyrazole and triazole compounds as ksp inhibitors
WO2011050095A3 (en) Prevention and treatment of post-operative cognitive dysfunction (pocd)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal